Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.59 |
| ▸ | THRA | P10827 | 14/20 | 0.59 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749394 | 0.86 | THRB (0.53) | THRBTHRAARPARP1 | |
| SCHEMBL24032753 | 0.86 | THRB (0.56) | THRBTHRAAR | |
| SCHEMBL2929101 | 0.85 | THRB (0.68) | THRBTHRA | |
| SCHEMBL21840370 | 0.78 | THRB (0.48) | THRBTHRA | |
| SCHEMBL2928883 | 0.77 | THRB (0.72) | THRBTHRACCR2 | |
| SCHEMBL24032735 | 0.77 | THRB (0.55) | THRBTHRA | |
| SCHEMBL31405662 | 0.75 | JAK2 (0.39) | THRBTHRAHTR1DHTR1BPARP1 | |
| SCHEMBL21840363 | 0.75 | THRB (0.48) | THRBTHRA | |
| SCHEMBL21749488 | 0.75 | THRB (0.48) | THRBTHRAARPARP1 | |
| SCHEMBL31054376 | 0.75 | THRB (0.46) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805005-B | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2025-07-24 | — | — | US | disclosed |
| CN-118290483-A | Pyridazinone compound and application thereof | 烟台药物研究所 | 2024-07-05 | — | — | CN | disclosed |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3863635-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3840755-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112839655-A | Thyroid hormone receptor beta agonist compounds | 拓臻股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-112805005-A | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| WO-2020041741-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885HTR1D 236/4885 |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885HTR1D 225/4885 |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885HTR1D 225/4885 |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885HTR1D 236/4885 |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885HTR1D 225/4885 |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885HTR1D 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.